Jefferies Upgrades Assembly Biosciences to Buy, Raises Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Dennis Ding has upgraded Assembly Biosciences (NASDAQ:ASMB) from Hold to Buy, significantly raising the price target from $2 to $35.
September 20, 2024 | 12:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies has upgraded Assembly Biosciences to Buy and increased the price target from $2 to $35, indicating strong confidence in the company's future performance.
The upgrade from Hold to Buy and the significant increase in the price target from $2 to $35 by Jefferies suggests a strong positive outlook for Assembly Biosciences. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100